Healio Rheuminations: Trials and Tribulations of Tumor Necrosis Factor, Part 2: Even More Necrosis

Trials and Tribulations of Tumor Necrosis Factor, Part 2: Even More Necrosis

Apr 17, 2019

This ripping yarn delves into the history of tumor necrosis factor in relation to rheumatoid arthritis with emphasis on the original studies that set the stage for the use of TNF inhibition in RA.

Intro :11
What we’ll cover here :16
Recap of Part 1 1:25
What I discovered when doing this episode 1:22
What this episode won’t address 2:40
Let the tale begin 3:12
A look at matrix metalloproteinases 3:32
A breakthrough in understanding RA 6:28
Two key players: Dr. Mark Feldman and Dr. Ravinder Maini 6:53
The first cytokine research conducted in RA: IL-1 8:00
The next cytokine: Tumor necrosis factor 11:16
What do we know about cytokine production within the joint? 14:33
IL-6 and TGF-beta 19:16
A bit about IL-10 23:57

*Visit Healio.com/rheum for daily news and updates*

How do we choose which cytokines to block to make improvements in RA? 25:16
What about in vivo data? 29:45
The history of infliximab 34:00
Infliximab is approved for RA treatment 45:13
TNF in RA: from bedside, to bench then back to bedside 46:06
It’s important to recognize the researchers who discovered these pathways 46:18
Remember the scientists next time you prescribe a TNF inhibitor 47:05
Read the latest news and commentary on Healio.com/rheumatology and Follow us on Twitter @HealioRheum and @HRheuminations for updates 47:34